Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $358000.0.

  • Vivos Therapeutics' Change in Accured Expenses rose 51149.43% to $358000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 349428.57%. This contributed to the annual value of -$39000.0 for FY2024, which is 10924.17% down from last year.
  • Vivos Therapeutics' Change in Accured Expenses amounted to $358000.0 in Q3 2025, which was up 51149.43% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' Change in Accured Expenses registered a high of $1.1 million during Q2 2025, and its lowest value of -$874000.0 during Q3 2022.
  • For the 5-year period, Vivos Therapeutics' Change in Accured Expenses averaged around $82263.2, with its median value being $68000.0 (2023).
  • As far as peak fluctuations go, Vivos Therapeutics' Change in Accured Expenses plummeted by 75686.27% in 2022, and later soared by 52580.65% in 2024.
  • Over the past 5 years, Vivos Therapeutics' Change in Accured Expenses (Quarter) stood at $320000.0 in 2021, then plummeted by 192.81% to -$297000.0 in 2022, then surged by 210.44% to $328000.0 in 2023, then fell by 22.56% to $254000.0 in 2024, then surged by 40.94% to $358000.0 in 2025.
  • Its last three reported values are $358000.0 in Q3 2025, $1.1 million for Q2 2025, and -$450000.0 during Q1 2025.